Table 3:

Subset of the Optic Neuritis Treatment Trial that was compared to patients receiving plasma exchange

Subset of the ONTT	Median Age (range)	Female %	Median Final VA	% 20/40 or better	% 20/200 or worse
20/200 or worse at enrollment (n=156)	31.1 (26–37)	77%	0 (20/20) (IQR, 0–0.1)	85%	6%
CF or worse at enrollment (n=70)	31.1 (26–36)	73%	0.00 (20/20) (IQR, 0–0.2)	79%	11%
VA of 20/200 or worse with minimal improvement after 3 days of IVMP (n=18)	30.4 (26–30)	72%	0.10 (20/25) (IQR, 0–0.1)	67%	17%
VA of 20/200 or worse with minimal improvement at 2 weeks after IVMP (n=11)	30.0 (26–38)	64%	0.44 (20/55) (IQR, 0.1–1.0)	36%	27%
VA of 20/200 or worse with at 4 weeks after IVMP (n=3)	30.0 (28–36)	100%	1.7 (CF) (IQR, 1.6–1.8)	0%	100%

Abbreviations: Optic Neuritis Treatment Trial (ONTT), visual acuity (VA), intravenous methylprednisolone (IVMP), interquartile (IQR)